Lung Cancer
Bendell JC et al. CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). Gastrointestinal Cancers Symposium 2021;Abstract TPS449.
Carrizosa DR et al. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions. ASCO 2022;Abstract 3006.
Dummer R et al. Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma. ESMO 2022;Abstract 7860.
Gogishvili M et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial. Nat Med 2022;[Online ahead of print]. Abstract
Gogishvili M et al. EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). ESMO 2021;Abstract LBA51.
Paz-Ares L et al. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. ESMO 2022;Abstract VP3-2022.
Paz-Ares LG et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. ASCO 2021;Abstract 9016.
Reck M et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. ASCO 2021;Abstract 9000.
Rodríguez-Abreu D et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: Protocol-specified final analysis from KEYNOTE-189. Ann Oncol 2021;32(7):881-95. Abstract
Sezer A et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021;397(10274):592-604. Abstract
Chronic Lymphocytic Leukemia and Lymphomas
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. EHA 2022;Abstract S148.
Allen PB et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 2021;137(10):1318-26. Abstract
Allen SM et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med 2022;387(4):310-20. Abstract
Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5):481-91. Abstract
Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract
Carlo-Stella C et al. Camidanlumab tesirine: Updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R CHL). EHA 2022;Abstract S201.
Dickinson M et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. ASCO 2022;Abstract 7500.
Dickinson M et al. Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: Pivotal phase II expansion results. EHA 2022;Abstract S220.
Dull J et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417-26. Abstract
Evens AM et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study. Haematologica 2022;107(5):1086-94. Abstract
Fornecker L-M et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial. J Clin Oncol 2022;[Online ahead of print]. Abstract
Kater AP et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022;1(7). Abstract
Kingsley E et al. Initial safety run-in results of the phase III LOTIS-5 Trial: Novel combination of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL. SOHO 2022;Abstract ABCL-320.
Mato AR et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. EHA 2022;Abstract S147.
Neelapu SS et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial. Nat Med 2022;28(4):735-42. Abstract
Rogers KA, Woyach JA. A CAPTIVATE-ing new regimen for CLL. Blood 2022;139(22):3229-30. Abstract
Seghal A et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An updated open-label, phase 2 study. Lancet Oncology 2022;23(8):1066-77. Abstract
Shanafelt TD et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial. Blood 2022;140(2):112-20. Abstract
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. ASCO 2022;Abstract 7539.
Tam CS et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort. Blood 2022;139(22):3278-89. Abstract
Tam CS et al. Ibrutinib plus venetoclax for the treatment of mantel-cell lymphoma. N Engl J Med 2018;378(13):1211-23. Abstract
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantel-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract
Wang ML et al. Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantel cell lymphoma in ZUMA-2. ASCO 2022;Abstract 7518.
Prostate and Bladder Cancers
Agarwal N et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 2022;18(4):425-36. Abstract
Armstrong AJ et al. Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial. ESMO 2022;Abstract 1372P.
Bajorin DF et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384(22):2102-14. Abstract
Balar AV et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22(7):919-30. Abstract
Chi KN et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. ASCO GU 2022;Abstract 12.
Daneshmand S et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: A phase I trial. Urol Oncol 2022;40(7):344.e1-9. Abstract
Davis ID et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ASCO 2022;Abstract LBA5004.
Fizazi K et al. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. ASCO 2021;Abstract 5000.
Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract
Friedlander TW et al. Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). ASCO 2021;Abstract 4528.
Hofman M et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). ASCO 2022;Abstract 5000.
Morris MJ et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). ASCO 2021;Abstract LBA4.
Powles T et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125-35. Abstract
Saad F et al. Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. ASCO GU 2022;Abstract 13.
Sartor O et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385(12):1091-103. Abstract
Siefker-Radtke AO et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. Lancet Oncol 2022;23(2):248-58. Abstract
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract
Smith MR et al. Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. ASCO GU 2022;Abstract 13.
Yu EY et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): A multicentre, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):872-82. Abstract
Renal Cell Carcinoma
Bauer TD et al. The oral HIF-2 alpha inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. ASCO GU 2021;Abstract 273.
Choueiri TK et al. Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma: Expanded efficacy analyses from KEYNOTE-564. ASCO 2022;Abstract 4512.
Jonasch E et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 2021;385(22):2036-46. Abstract
CAR T-Cell and Bispecific Therapy for Multiple Myeloma
Agha M et al. CARTITUDE-2 cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. EHA 2022;Abstract S185.
Dimopoulos MA et al. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2022;22(7):460-73. Abstract
Hillengass J et al. Ciltacabtagene autoleucel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 biological correlative analyses and updated clinical data. EHA 2022;Abstract P959.
Lonial S et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study. ASCO 2022;Abstract 8019.
Minnema M et al. Talquetamab, a G protein-coupled receptor family C group 5 member D X CD3 bispecific antibody, in relapsed/refractory multiple myeloma: Updated efficacy and safety results from MONUMENTAL-1. EHA 2022;Abstract S182.
Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. ASCO 2022;Abstract LBA4.
Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract
Usmani SZ et al. Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. ASCO 2022;Abstract 8028.
van de Donk N et al. Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: Updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab. EHA 2022;Abstract S183.
Hepatobiliary Cancers
Abou-Alfa GK et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1(8). Abstract
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39(1):1-10. Abstract
Finn RS et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). ASCO 2021;Abstract 267.
Finn R et al. Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). ESMO 2022;Abstract LBA34.
Kelley RK et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(8):995-1008. Abstract
Oh D-Y et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1(8). Abstract
Oh D-Y et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). ESMO 2022;Abstract 56P.
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). ASCO 2022;Abstract 4006.
Valle JW et al. Biliary tract cancer. Lancet 2021;397(10272):428-44. Abstract
Vogel A et al. Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202. ESMO 2022;Abstract O-2.
Breast Cancer
Bardia A et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Can Res 2021;27(15):4177-85. Abstract
Bartsch R et al. Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial. ESMO 2021;Abstract 280P.
Cortes J et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386(12):1143-54. Abstract
Curigliano G et al. Tucatinib versus placebo added trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with or without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract
Garufi G et al. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? Cancer Treat Rev 2022;110:102454. Abstract
Griguolo G et al. Gene-expression signatures to inform neoadjuvant treatment decision in HER+/HER2- breast cancer: Available evidence and clinical implications. Cancer Treat Rev 2022;102:102323. Abstract
Hamilton EP et al. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. ASCO 2022;Abstract 1000.
Hortobagyi GN et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 2022;386(10):942-50. Abstract
Kalinsky K et al. A randomized phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients with unresectable or metastatic hormone receptor-positive (HR+), HER2-negative breast cancer (MBC): MAINTAIN trial. ASCO 2022;Abstract LBA1004.
Kalinsky K et al. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer with recurrence score (RS) of ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER). SABCS 2021;Abstract GS2-07.
Litton JK et al. Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA 1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study. ASCO 2021;Abstract 554.
Martin et al. Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: A prespecified analysis of the monarchE randomized clinical trial. JAMA Oncol 2022;8(8):1190-4. Abstract
Mittendorf EA et al. Impact of RxPONDER and monarchE on the surgical management of the axilla in patients with breast cancer. J Clin Oncol 2022;40(29):3361-5. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Schmid P et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386(6):556-67. Abstract
Tung NM et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol 2021;39(26):2959-61. Abstract
Tutt AN et al. Pre-specified event driven analysis of overall survival (OS) I the OLYMPIA phase III trial of adjuvant olaparib (OL) in germline BRCA 1/2 mutation (gBRCAm) associated breast cancer. ESMO 2022;Abstract VP1-2022.
Endometrial Cancer
Maio M et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study. ESMO 2022;Abstract 113P.
Makker V et al. Randomized phase III study of maintenance selinexor vs placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis of molecular classification. ASCO 2022;Abstract 5511.
Makker V et al. Updated efficacy and safety of lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. ESMO 2022;Abstract 525MO.
O’Malley D et al. Pembrolizumab for microsatellite instability-high or mismatch repair deficient advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158. ESMO 2022;Abstract 546P.
Ovarian Cancer
Banerjee S et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO 2022;Abstract 529MO.
Drew Y et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). ESMO 2020;Abstract 814MO.
Drew Y et al. Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). ESMO 2019;Abstract 4563.
Monk BJ et al. ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer 2021;31(12):1589-94. Abstract
Randall LM et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.
Selle F et al. OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis — An exploratory joint analysis of the BRCA and Non-BRCA cohorts. ASCO 2022;Abstract 5558.
Gastrointestinal Cancers
Andre T et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study. Gastrointestinal Cancers Symposium 2022;Abstract 244.
Cercek A et al. PD-1 blockade as curative-intent therapy in mismatch repair deficient locally advanced rectal cancer. ASCO 2022;Abstract LBA5.
Cercek A et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363-76. Abstract
Golan T et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Gastrointestinal Cancers Symposium 2021;Abstract 378.
Janjigian YY et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40. Abstract
Janjigian YY et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727-30. Abstract
Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384(13):1191-203. Abstract
Ku GY et al. Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in Western patients with HER2-positive unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzuamb-containing regimen. ESMO 2022;Abstract 1205M0.
Leidner R et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med 2022;386(22):2112-9. Abstract
Morris VK, Strickler JH. Use of circulating cell-free DNA to guide precision medicine in patients with colorectal cancer. Annu Rev Med 2021;72:399-413. Abstract
Reiss KA et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 2021;39(22):2497-505. Abstract
Strickler JH et al. Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. ESMO GI 2022;Abstract LBA27.
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.
Melanoma
Arance A et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol 2022;[Online ahead of print]. Abstract
Amaria RN et al. Neoadjuvant systemic therapy in melanoma: Recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 2019;20(7):e378-89. Abstract
Atkins MB et al. DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): A phase III trial — ECOG-ACRIN EA6134. ASCO 2022;Abstract 356154.
Dummer R et al. Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma. ESMO 2022;Abstract 7860.
Eggermont AMM et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378(19):1789-801. Abstract
Garbe C et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: Implications for adjuvant treatment. J Clin Oncol 2022;[Online ahead of print]. Abstract
Hamid O et al. Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma. ESMO 2022;Abstract 790M0.
Long GV et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017;377(19):1813-23. Abstract
Menzies AM et al. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 2021;27(2):301-9. Abstract
Tawbi HA et al. Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047. ASCO 2022;Abstract 9505.
Tetzlaff MT et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Onc 2018;29(8):1861-68. Abstract
van Akkooi ACJ et al. Neoadjuvant systemic therapy (NAST) in patients with melanoma: Surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol 2022;29(6):3694-708. Abstract
Weber J et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377(19):1824-35. Abstract
Zhu L et al. Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges. Oncogenesis 2021;10(7):47. Abstract